• Strategy on track targeting double digit FY26 ARR growth
• Simplifying for scale with new leadership appointments
• Advancing AI-powered solutions like Autonomous Coding, Data Entry, and Evolve platform

Beamtree Holdings Limited (ASX: BMT) applies deep clinical, coding and data expertise combined with AI to help hospitals and pathology labs improve clinical quality, coding accuracy, and reimbursement outcomes. 1H FY26 saw parallel advancement of Autonomous Coding Solution (ACS), Autonomous Data Entry (ADE), and the UK Evolve platform launch, alongside scaling of core Diagnostics, Knowledge Networks, and Coding Quality products. Key highlights include: Evolve - UK NHS Confederation collaborative AI powered benchmarking and analytics platform now live targeting 10+ trusts in 2H FY26; ACS - trials finalising, targeting new customers in Australia in 2H FY26; ADE - trial nearing completion, mobilising to commercialise in 2H FY26; Diagnostics - Abbott momentum with two additional enterprise licenses; Coding Quality - PICQ® Audit extended to private hospitals; Knowledge Networks - five new Health Roundtable customers, with 5,000 monthly users. The company continues to invest in leadership and capability to support greater scale, predictability, and growth, with new appointments of a GM Sales (ANZ) and a CFO. 1H FY26 saw 10% growth in recurring revenue and a flat ARR of $28M due to enterprise contract timing and churn of legacy products. Beamtree enters 2H FY26 focused on converting a robust late-stage pipeline to revenue, targeting double digit ARR growth.

Beamtree's FY26 ARR target remains at double digit growth.

Beamtree is well positioned for accelerating ARR growth from a clear baseline in 2H FY26 and beyond, with customer-led AI solutions advancing to commercial deployment, a committed team, a simplified operating and reporting framework in place, and strong demand across all geographies.